Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hedyotis diffusa extract is derived from the whole plant Hedyotis diffusa (also known as Oldenlandia diffusa), widely used in traditional East Asian medicine for its therapeutic properties. The extract contains multiple bioactive compounds, including anthraquinones, iridoids, flavonoids, polysaccharides, and triterpenes. Reported **mechanisms of action** include induction of apoptosis in cancer cells, inhibition of tumor proliferation and metastasis, suppression of inflammatory pathways, and modulation of immune responses[2][3][5][6]. Key molecular targets and related pathways reported include CTNNB1 (β-catenin), STAT3, CASP8, APC, AKT/ERK, and PI3K/AKT[2][5]. Studies confirm anti-cancer effects in models of lung adenocarcinoma, liver cancer, colorectal cancer, as well as immunomodulatory and anti-inflammatory effects in vitro and in animal models[2][3][4][5][6]. Hedyotis diffusa extract is classed as a **dietary supplement** in most global jurisdictions and is used as a complementary therapy, especially in cancer management, autoimmune conditions, and chronic inflammatory states.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hedyotis diffusa extract.